Kailera Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
Kailera Therapeutics reported strong Q2 2026 progress, advancing its ribupatide injection and oral programs, with cash runway extending into mid-2028.